Inventor · disambiguated record
David Wyn Watson
Also filed as: WATSON DAVID · WATSON DAVID WYN
21 granted patents·4 pending applications·152 citations·filing 2011–2024
96Inventor score
Top patents by PatentIndex Score
25 records- 0198US12054465B2Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitorsASTRAZENECA AB·Filed 2023·Granted Aug 6, 2024·3 cites·21 claims
- 0298US11814359B2Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitorsASTRAZENECA AB·Filed 2022·Granted Nov 14, 2023·4 cites·21 claims
- 0398US11773069B2Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitorsASTRAZENECA AB·Filed 2022·Granted Oct 3, 2023·6 cites·23 claims
- 0498US11680049B2Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitorsASTRAZENECA AB·Filed 2022·Granted Jun 20, 2023·5 cites·14 claims
- 0598US11117874B2Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitorsASTRAZENECA AB·Filed 2020·Granted Sep 14, 2021·15 cites·60 claims
- 0698US10669245B2Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides dipeptidyl peptidase 1 inhibitorsASTRAZENECA AB·Filed 2019·Granted Jun 2, 2020·16 cites·16 claims
- 0797US11673871B2Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitorsASTRAZENECA AB·Filed 2022·Granted Jun 13, 2023·5 cites·20 claims
- 0897US11673872B2Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitorsASTRAZENECA AB·Filed 2022·Granted Jun 13, 2023·5 cites·14 claims
- 0997US11667615B2Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitorsASTRAZENECA AB·Filed 2021·Granted Jun 6, 2023·5 cites·15 claims
- 1097US11655222B2Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitorsASTRAZENECA AB·Filed 2022·Granted May 23, 2023·5 cites·20 claims
- 1197US11655221B2Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitorsASTRAZENECA AB·Filed 2022·Granted May 23, 2023·5 cites·22 claims
- 1297US11655223B2Certain (2S)-N-[(1 s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitorsASTRAZENECA AB·Filed 2022·Granted May 23, 2023·5 cites·21 claims
- 1397US11655224B2Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitorsASTRAZENECA AB·Filed 2022·Granted May 23, 2023·5 cites·20 claims
- 1497US10287258B2Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitorsASTRAZENECA AB·Filed 2017·Granted May 14, 2019·18 cites·6 claims
- 1597US9522894B2Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitorsASTRAZENECA AB·Filed 2015·Granted Dec 20, 2016·25 cites·8 claims
- 1695US10544132B2Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activityASTEX THERAPEUTICS LTD·Filed 2016·Granted Jan 28, 2020·10 cites·27 claims
- 1792US10981898B2Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activityASTEX THERAPEUTICS LTD·Filed 2019·Granted Apr 20, 2021·4 cites·27 claims
- 1892US10526311B2Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activityASTEX THERAPEUTICS LTD·Filed 2016·Granted Jan 7, 2020·6 cites·25 claims
- 1991US2024336582A1Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitorsASTRAZENECA AB·Filed 2024·Application pending·0 cites
- 2087US2023250071A1Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitorsASTRAZENECA AB·Filed 2023·Application pending·0 cites
- 2185US11261171B1Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activityASTEX THERAPEUTICS LTD·Filed 2019·Granted Mar 1, 2022·2 cites·24 claims
- 2282US2025092027A1Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activityASTEX THERAPEUTICS LTD·Filed 2024·Application pending·0 cites
- 2370US12071429B2Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activityASTEX THERAPEUTICS LTD·Filed 2021·Granted Aug 27, 2024·0 cites·27 claims
- 2468US9181234B2Antibacterial compoundsPALMER JAMES T·Filed 2011·Granted Nov 10, 2015·3 cites·17 claims
- 2567US2022106287A1Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activityASTEX THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when David Wyn Watson files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →